STOCK TITAN
  1. Home
  2. News
  3. PTN

Palatin Technologies Inc. - PTN STOCK NEWS

Welcome to our dedicated news page for Palatin Technologies (Ticker: PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Technologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palatin Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palatin Technologies's position in the market.

News
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) announces positive Phase 3 study results for PL9643 in treating dry eye disease. The study showed statistically significant improvements in pain and secondary symptom endpoints, including safety and tolerability. Discussions with the FDA for regulatory approval are planned for 2Q 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.77%
Tags
clinical trial
-
News
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Rhea-AI Summary
Palatin Technologies, Inc. (PTN) announces positive results from its PL9643 MELODY-1 pivotal Phase 3 clinical trial for dry eye disease. The trial met co-primary symptom endpoint with statistical significance. PL9643 showed superiority over vehicle in multiple symptom endpoints and demonstrated excellent safety. Future discussions with FDA are planned.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-38.29%
Tags
clinical trial
-
News
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Rhea-AI Summary
Palatin Technologies, Inc. focuses on developing its Melanocortin Receptor System Pipeline, with upcoming Phase 3 and Phase 2 clinical study results expected in 2024. The company completed an asset sale of Vyleesi for up to $171 million and raised $10 million through a Registered Direct Offering. Financially, Palatin reported increased revenue and gross product sales, offset by higher operating expenses and a net loss of $7.8 million for the quarter ended December 31, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-23.91%
Tags
earnings
News
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
Rhea-AI Summary
Palatin Technologies, Inc. (PTN) will release its Q2 fiscal year 2024 operating results on February 15, 2024, with a conference call and webcast to follow. The call will cover the company's results and ongoing programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.72%
Tags
conferences earnings
-
News
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Rhea-AI Summary
Palatin Technologies, Inc. announced the database lock for its PL9643 MELODY-1 pivotal Phase 3 clinical trial evaluating the safety and efficacy of PL9643 versus vehicle in the treatment of dry eye disease. The top-line results are expected to be reported later in February. The trial is a multi-center, randomized, double–masked and vehicle–controlled study, that enrolled 575 patients at sites in the U.S. The Phase 3 program also includes the Phase 3 safety and efficacy study MELODY-2 and the open label MELODY-3 study, which are anticipated to commence patient enrollment in the second half of calendar year 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.67%
Tags
clinical trial
-
News
Palatin Announces Closing of $10 Million Registered Direct Offering
Rhea-AI Summary
Palatin Technologies, Inc. (PTN) closed a registered direct offering of 1,831,503 shares of common stock with gross proceeds of approximately $10 million. The company also issued warrants to purchase up to an aggregate of 1,831,503 shares at an exercise price of $5.46 per share. The net proceeds will be used for general corporate purposes. The offering was conducted pursuant to a shelf registration statement on Form S-3 and a prospectus supplement was filed with the SEC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.71%
Tags
offering
News
Palatin Announces $10 Million Registered Direct Offering
Rhea-AI Summary
Palatin Technologies, Inc. (PTN) has entered into a definitive agreement for the issuance and sale of 1,831,503 shares of its common stock at a purchase price of $5.46 per share, along with warrants to purchase an additional 1,831,503 shares. The offering is expected to raise significant capital for the company's development of first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
offering
-
News
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) provided a corporate update, highlighted key calendar year 2023 accomplishments, and outlined anticipated calendar year 2024 clinical development milestones. The company is well-positioned for a pivotal and transformative year, focusing on DED, UC, obesity, and male sexual dysfunction. Topline data readouts for various clinical studies are expected in 2024. The company also completed an asset sale to Cosette Pharmaceuticals for up to $171 million in December 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.73%
Tags
none
-
News
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
Rhea-AI Summary
Cosette Pharmaceuticals, Inc. (PTN) has completed the acquisition of Vyleesi®, the only FDA-approved as-needed treatment for the approximately 6 million premenopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD). The acquisition adds another commercial stage, patent-protected product to Cosette’s rapidly expanding women’s health portfolio. Vyleesi® has experienced 8 consecutive quarters of double-digit prescription growth and includes 5 Orange Book listed patents with protection up to 2041.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
acquisition
News
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) sells Vyleesi® to Cosette Pharmaceuticals for $12 million upfront and up to $159 million in sales-based milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
none
Stock PTN logo
Palatin Technologies Inc.

NYSE:PTN

PTN Rankings

#5005 Ranked by Market Cap
#5020 Ranked by Stock Gains
N/A Ranked by Dividends

PTN Stock Data

30.98M
15.54M
3.35%
10.72%
9.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Cranbury

About PTN

palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy